NasdaqGM:LGNDPharmaceuticals
A Look At Ligand Pharmaceuticals (LGND) Valuation As Royalty Growth And Investment Plans Take Focus
Royalty growth outlook and capital deployment signal focus areas for investors
Ligand Pharmaceuticals (LGND) recently highlighted an expected 40% royalty revenue increase in 2026 and a 23% compound annual growth rate projection through 2030, alongside more than US$1b in deployable capital for new investments.
See our latest analysis for Ligand Pharmaceuticals.
Those royalty growth projections and the large capital pool are arriving after a sharp move in the stock, with a 1 year total...